Arrowhead Historical Balance Sheet

0HI3 Stock

26.30 4.45 20.37%

Trend analysis of Arrowhead Pharmaceuticals Corp balance sheet accounts such as Short Long Term Debt Total of 139.1 M, Other Current Liabilities of 70.2 M or Total Current Liabilities of 127.3 M provides information on Arrowhead Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Arrowhead Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Arrowhead Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Arrowhead Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arrowhead Pharmaceuticals is a good buy for the upcoming year.

Arrowhead Pharmaceuticals Inventory

(18.48 Million)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.

About Arrowhead Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Arrowhead Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Arrowhead Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Arrowhead Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Arrowhead currently owns. An asset can also be divided into two categories, current and non-current.

Arrowhead Pharmaceuticals Balance Sheet Chart

At this time, Arrowhead Pharmaceuticals' Cash is comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 417.8 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 229.4 K in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Current Deferred Revenue

Total Assets

Total assets refers to the total amount of Arrowhead Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Arrowhead Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Arrowhead Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Arrowhead Pharmaceuticals Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most accounts from Arrowhead Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Cash is comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 417.8 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 229.4 K in 2024.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	81.6M	115.2M	132.4M	139.1M
Total Assets	691.9M	765.6M	880.4M	924.4M

Short Long Term Debt Total Total Assets

Arrowhead Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Non Current Liabilities Total	Good Will	Short Term Investments
Total Assets		0.9	0.87	0.91	0.78	0.87	0.04	-0.92	0.79	0.66	0.99	0.25	0.99	0.4	0.87	-0.73	0.85	0.97	0.92	0.99	0.81	0.26	0.36	0.87	0.5	0.97
Short Long Term Debt Total	0.9		0.87	0.76	0.5	0.99	0.38	-0.88	0.9	0.38	0.91	0.23	0.87	0.1	0.72	-0.92	0.87	0.9	0.95	0.87	0.86	0.24	0.02	0.94	0.44	0.95
Other Current Liab	0.87	0.87		0.69	0.45	0.81	0.27	-0.87	0.61	0.39	0.89	0.64	0.85	0.18	0.74	-0.88	0.98	0.88	0.95	0.85	0.65	0.65	0.28	0.96	0.42	0.92
Total Current Liabilities	0.91	0.76	0.69		0.75	0.74	-0.16	-0.81	0.72	0.74	0.9	0.1	0.91	0.59	0.82	-0.55	0.69	0.86	0.82	0.91	0.85	0.11	0.56	0.72	0.44	0.81
Total Stockholder Equity	0.78	0.5	0.45	0.75		0.49	-0.4	-0.63	0.54	0.8	0.72	-0.15	0.81	0.47	0.78	-0.19	0.39	0.75	0.48	0.81	0.53	-0.14	0.39	0.38	0.45	0.66
Property Plant And Equipment Net	0.87	0.99	0.81	0.74	0.49		0.42	-0.86	0.94	0.33	0.89	0.12	0.83	0.08	0.7	-0.9	0.81	0.88	0.91	0.84	0.83	0.13	-0.07	0.9	0.45	0.93
Net Debt	0.04	0.38	0.27	-0.16	-0.4	0.42		-0.17	0.32	-0.71	0.14	0.14	-0.07	-0.29	-0.16	-0.55	0.26	0.08	0.29	-0.06	0.02	0.12	-0.62	0.39	-0.08	0.27
Retained Earnings	-0.92	-0.88	-0.87	-0.81	-0.63	-0.86	-0.17		-0.78	-0.51	-0.91	-0.28	-0.9	-0.26	-0.91	0.8	-0.86	-0.96	-0.9	-0.9	-0.75	-0.3	-0.23	-0.87	-0.58	-0.93
Accounts Payable	0.79	0.9	0.61	0.72	0.54	0.94	0.32	-0.78		0.36	0.79	-0.17	0.76	0.07	0.66	-0.74	0.63	0.8	0.76	0.77	0.81	-0.16	-0.17	0.73	0.46	0.83
Cash	0.66	0.38	0.39	0.74	0.8	0.33	-0.71	-0.51	0.36		0.56	0.05	0.73	0.39	0.71	-0.14	0.41	0.61	0.44	0.73	0.61	0.06	0.63	0.33	0.43	0.46
Non Current Assets Total	0.99	0.91	0.89	0.9	0.72	0.89	0.14	-0.91	0.79	0.56		0.27	0.96	0.43	0.83	-0.77	0.86	0.96	0.94	0.97	0.78	0.28	0.33	0.9	0.46	0.98
Non Currrent Assets Other	0.25	0.23	0.64	0.1	-0.15	0.12	0.14	-0.28	-0.17	0.05	0.27		0.25	0.0	0.2	-0.47	0.64	0.26	0.46	0.23	0.07	1.0	0.41	0.53	0.04	0.3
Cash And Short Term Investments	0.99	0.87	0.85	0.91	0.81	0.83	-0.07	-0.9	0.76	0.73	0.96	0.25		0.36	0.9	-0.7	0.83	0.97	0.89	1.0	0.82	0.26	0.38	0.84	0.52	0.94
Net Receivables	0.4	0.1	0.18	0.59	0.47	0.08	-0.29	-0.26	0.07	0.39	0.43	0.0	0.36		0.27	0.07	0.11	0.29	0.28	0.37	0.15	0.01	0.7	0.18	0.12	0.27
Common Stock Shares Outstanding	0.87	0.72	0.74	0.82	0.78	0.7	-0.16	-0.91	0.66	0.71	0.83	0.2	0.9	0.27		-0.55	0.73	0.94	0.75	0.89	0.71	0.21	0.38	0.68	0.64	0.82
Inventory	-0.73	-0.92	-0.88	-0.55	-0.19	-0.9	-0.55	0.8	-0.74	-0.14	-0.77	-0.47	-0.7	0.07	-0.55		-0.9	-0.75	-0.91	-0.69	-0.7	-0.48	0.07	-0.95	-0.31	-0.84
Other Current Assets	0.85	0.87	0.98	0.69	0.39	0.81	0.26	-0.86	0.63	0.41	0.86	0.64	0.83	0.11	0.73	-0.9		0.86	0.95	0.83	0.71	0.65	0.27	0.96	0.41	0.89
Other Stockholder Equity	0.97	0.9	0.88	0.86	0.75	0.88	0.08	-0.96	0.8	0.61	0.96	0.26	0.97	0.29	0.94	-0.75	0.86		0.91	0.97	0.78	0.27	0.28	0.87	0.59	0.97
Total Liab	0.92	0.95	0.95	0.82	0.48	0.91	0.29	-0.9	0.76	0.44	0.94	0.46	0.89	0.28	0.75	-0.91	0.95	0.91		0.89	0.8	0.46	0.27	0.99	0.42	0.95
Total Current Assets	0.99	0.87	0.85	0.91	0.81	0.84	-0.06	-0.9	0.77	0.73	0.97	0.23	1.0	0.37	0.89	-0.69	0.83	0.97	0.89		0.82	0.24	0.38	0.83	0.52	0.94
Short Term Debt	0.81	0.86	0.65	0.85	0.53	0.83	0.02	-0.75	0.81	0.61	0.78	0.07	0.82	0.15	0.71	-0.7	0.71	0.78	0.8	0.82		0.08	0.26	0.74	0.39	0.76
Common Stock	0.26	0.24	0.65	0.11	-0.14	0.13	0.12	-0.3	-0.16	0.06	0.28	1.0	0.26	0.01	0.21	-0.48	0.65	0.27	0.46	0.24	0.08		0.42	0.53	0.03	0.31
Current Deferred Revenue	0.36	0.02	0.28	0.56	0.39	-0.07	-0.62	-0.23	-0.17	0.63	0.33	0.41	0.38	0.7	0.38	0.07	0.27	0.28	0.27	0.38	0.26	0.42		0.18	0.06	0.18
Non Current Liabilities Total	0.87	0.94	0.96	0.72	0.38	0.9	0.39	-0.87	0.73	0.33	0.9	0.53	0.84	0.18	0.68	-0.95	0.96	0.87	0.99	0.83	0.74	0.53	0.18		0.39	0.93
Good Will	0.5	0.44	0.42	0.44	0.45	0.45	-0.08	-0.58	0.46	0.43	0.46	0.04	0.52	0.12	0.64	-0.31	0.41	0.59	0.42	0.52	0.39	0.03	0.06	0.39		0.47
Short Term Investments	0.97	0.95	0.92	0.81	0.66	0.93	0.27	-0.93	0.83	0.46	0.98	0.3	0.94	0.27	0.82	-0.84	0.89	0.97	0.95	0.94	0.76	0.31	0.18	0.93	0.47

Click cells to compare fundamentals

Arrowhead Pharmaceuticals Account Relationship Matchups

Arrowhead Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	522.5M	710.1M	691.9M	765.6M	880.4M	924.4M
Other Current Liab	32.8M	33.3M	100.4M	58.2M	66.9M	70.2M
Total Current Liabilities	40.7M	146.5M	74.1M	105.5M	121.3M	127.3M
Total Stockholder Equity	461.8M	408.8M	106.0M	271.3M	312.0M	327.6M
Property Plant And Equipment Net	47.0M	66.0M	168.6M	335.6M	385.9M	405.2M
Net Debt	(122.4M)	(158.9M)	(26.4M)	4.3M	3.9M	4.0M
Retained Earnings	(503.8M)	(644.7M)	(820.8M)	(1.0B)	(923.4M)	(877.3M)
Accounts Payable	6.8M	9.5M	2.9M	35.9M	41.2M	43.3M
Cash	143.6M	184.4M	108.0M	110.9M	127.5M	133.9M
Non Current Assets Total	200.1M	325.6M	315.5M	346.0M	397.9M	417.8M
Non Currrent Assets Other	265.4K	272K	29.1M	210K	241.5K	229.4K
Cash And Short Term Investments	315.5M	367.8M	376.4M	403.6M	464.2M	487.4M
Net Receivables	661.4K	845.7K	10.3M	1.4M	1.6M	970.9K
Common Stock Shares Outstanding	100.7M	103.7M	105.4M	106.8M	122.8M	128.9M
Liabilities And Stockholders Equity	522.5M	710.1M	691.9M	765.6M	880.4M	924.4M
Inventory	3.3M	4.3M	4.4M	(21.6M)	(19.5M)	(18.5M)
Other Current Assets	6.0M	6.6M	27.5M	15.9M	18.3M	19.2M
Other Stockholder Equity	965.4M	1.1B	1.2B	1.3B	1.5B	1.6B
Total Liab	60.7M	301.3M	586.0M	478.4M	550.1M	577.7M
Total Current Assets	322.4M	384.6M	376.4M	419.5M	482.4M	506.6M
Accumulated Other Comprehensive Income	18.4K	(69K)	(136K)	(3.2M)	(2.9M)	(2.8M)
Short Term Debt	1.1M	4.5M	5.6M	10.6M	12.1M	12.8M
Common Stock	194.7K	197K	106.0M	200K	230K	218.5K
Current Deferred Revenue	19.3M	111.1M	74.1M	866K	995.9K	946.1K
Non Current Liabilities Total	20.0M	154.8M	511.9M	372.9M	428.9M	450.3M
Short Term Investments	171.9M	183.4M	268.4M	292.7M	336.6M	353.5M
Intangible Assets	15.4M	13.7M	12.0M	10.3M	11.8M	10.2M
Other Liab	1.9M	8.7M	131.5M	56.0M	64.3M	44.0M
Net Tangible Assets	446.4M	395.2M	386.6M	261.1M	300.2M	291.5M
Capital Surpluse	582.9M	664.1M	965.4M	1.1B	1.2B	831.6M
Property Plant Equipment	47.0M	66.0M	168.6M	335.6M	385.9M	405.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC